Background: Neuropsychological deficits in schizophrenia appear to predate clinical symptoms of the disease and become more pronounced at illness onset, but controversy exists about whether and when further neuropsychological progression may occur.
T HERE IS a high prevalence of neuropsychological impairment in persons with schizophrenia, ranging from mild deficits to frank dementia. [1] [2] [3] [4] [5] Consistent with a neurodevelopmental view, some such deficits appear to predate clinical symptoms and exacerbate with typical illness onset during late adolescence or early adulthood. [6] [7] [8] There remains considerable controversy about whether there is further progression of neuropsychological deficits after the onset of the illness. 9 With a few notable exceptions, [10] [11] [12] cross-sectional studies generally have not found evidence of increased neuropsychological deficits in association with duration of illness or (relative to age-matched controls) in older than in younger patients with schizophrenia. 2, [13] [14] [15] [16] [17] Definitive answers to questions regarding possible pro-gression of neuropsychological deficits in schizophrenia must come from longitudinal studies. The available studies, however, provide conflicting results and have a variety of methodologic limitations (eg, small or nonrepresentative samples, no controls, brief follow-ups, and/or limited neuropsychological testing). 2, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Both neurodevelopmental and neurodegenerative views of neuropsychological deficits in schizophrenia seemingly remain viable. 10 While progression of deficit after illness onset clearly is not universal, or even typical of the disorder, a subset of persons with schizophrenia may evidence cognitive deterioration over time. The size and nature of that subgroup are unclear, but the existing studies suggest that potentially relevant issues include subject age, duration of illness, level of initial neuropsychological impairment, improvement or deteriora-tion in clinical status, and emergence of neurolepticinduced dyskinesia. 2, [29] [30] [31] The current study addressed these issues by longitudinally observing sizable samples of ambulatory schizophrenic patients and normal comparison subjects (NCs) with a comprehensive battery of neuropsychological tests. These groups were compared with respect to test-retest correlations and neuropsychological stability over shorter vs longer follow-up periods. Also compared were schizophrenic subgroups defined on the basis of demographic and clinical variables, as well as initial level of neuropsychological functioning. Finally, data from NCs were used to define normal test-retest variability; these definitions were then applied to the results of the schizophrenic subjects, in an attempt to identify and characterize any subgroup of individuals who demonstrated unusual decreases in neuropsychological functioning over time. Table 1 , there were small but statistically significant group differences in age, education, and test-
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SUBJECTS AND METHODS
SUBJECTS
Subjects included 142 outpatients with schizophrenia and 206 NCs, who had completed at least 2 comprehensive neuropsychological evaluations. Each patient and NC was a participant in 1 of 3 university-based clinical research centers, and most have contributed baseline neuropsychological data to previously published reports. [37] [38] [39] [40] Diagnostic procedures for subjects in both groups included the Structured Clinical Interview for the DSM-III-R or DSM-IV. 41, 42 Subjects were also screened by a physician using a physical examination and a structured medical history questionnaire; those with current or past medical conditions likely to affect central nervous system functioning (such as significant head injuries, seizure disorder, or acute medical conditions), as well as those meeting DSM-III-R 43 or DSM-IV 44 criteria for current alcohol or substance abuse or dependence, were excluded. All subjects provided written informed consent before participation in the research.
NEUROPSYCHOLOGICAL EXAMINATIONS
The patients and NCs were assessed with an annually scheduled comprehensive neuropsychological test battery (in actuality, the mean test-retest interval between the first 2 of these evaluations was 16.6 months [SD, 8.6 months; range, 6-81 months]). Eighty-nine schizophrenic patients and 119 NCs completed at least 1 additional neuropsychological follow-up evaluation. The total number of evaluations ranged from 2 to 10 (mean, 3.38; SD, 1.57; median, 3.00). The interval between the first and last neuropsychological evaluations ranged from 6 to 125 months and was not significantly different for the schizophrenic patients vs NCs (mean and SD, 37.0 and 22.3 months vs 37.1 and 25.7 months, respectively; t 346 =0.05, P=.96).
Except where otherwise indicated, each of the neuropsychological measures was part of the expanded Halstead-Reitan battery, and details of administration and scoring were as described by Reitan and Wolfson 45 and Heaton and colleagues. 46, 47 The individual measures were grouped into 7 ability areas based on the neuropsychological constructs that they are putatively designed to measure. The verbal ability area included the Aphasia Screening Test, Boston Naming Test, and the Controlled Oral Word Association Test. 48, 49 Scores on the latter test were unavailable for a few subjects, so the Thurstone (written) Word Fluency task was substituted for 2 subjects at the baseline evaluation and 5 subjects at the first follow-up. The psychomotor ability area included the block design, object assembly, and digit symbol subtests from the Wechsler Adult Intelligence Scale-Revised (WAIS-R) 50 52 The motor skills ability area included the right-and left-hand scores on Finger Tapping, Grooved Pegboard, and Hand Dynamometer.
We also had data from baseline and at least 1 retest evaluation with an even more comprehensive neuropsychological evaluation on a subsample of patients and NCs, permitting calculation of the WAIS-R Verbal, Performance, and Full-Scale IQs 50 for 81 patients and 86 NCs, and the Halstead-Reitan battery Average Impairment Rating 53 for 74 patients and 82 NCs.
Neuropsychological test raw scores were converted to standardized scaled scores (mean and SD, 10 and 3, respectively, in normal subjects) and age-, education-, and sex-corrected T-scores (mean and SD, 50 and 10, respectively, in normal subjects), by means of previously published normative data. [46] [47] [48] 51, 54 We then calculated the mean scaled scores and T-scores within each ability area, and a composite global scaled score and T-score.
PSYCHIATRIC AND MOTOR SYMPTOM RATINGS
Longitudinal ratings of psychiatric symptoms were also obtained for a subset (n = 116) of the schizophrenic patients, as well as a smaller subset of NCs (n = 86 to 88). Psychiatric symptom rating scales included the Brief Psychiatric Rating Scale 55 and the Scales for the Assessment of Positive and Negative Symptoms (SAPS and SANS, respectively). 56 Tardive dyskinesia was assessed with the Abnormal Involuntary Movement Scale. 57
STATISTICAL METHODS AND ANALYSES
The test-retest reliability of neuropsychological measures and symptom rating scales was assessed in terms of retest interval. There were no significant differences in sex or ethnicity. As expected, the patients had substantially greater global neuropsychological impairment and more severe clinical symptoms than the NCs.
There were some differences between subjects with and without WAIS-R IQ scores and Average Impairment Rating scores, which primarily reflected different demographic recruiting emphases and slight differences in neuropsychological protocols among the 3 research centers from which the present sample was drawn. Schizophrenic patients who had WAIS-R IQ scores were different from those without only in age 4.9] , respectively; t 204 = 3.46, P = .001); and were more likely to be male McGraw and Wong's 58 intraclass correlation coefficients for degree of consistency between measurements at the baseline and 1-year follow-up evaluations. The magnitudes of the intraclass correlation coefficients for the neuropsychological and symptom rating scale scores of patients and NCs were compared by means of Fisher r-to-z transformations for intraclass correlation coefficients. 58 The neuropsychological scaled scores, rather than T-scores, were used for these analyses, since the latter would underestimate the stability of neuropsychological performance by removing variance related to the stable traits of education and sex.
To examine the effects of length of follow-up on neuropsychological stability, patients and NCs were divided into diagnosis-by-length of follow-up groups, wherein "short" follow-up was defined as less than 36 months and "long" follow-up was defined as 36 months or longer. This yielded 121 NCs and 75 schizophrenic patients with short follow-up (mean, 19.5 months; SD, 6.8 months) and 85 NCs and 67 schizophrenic patients with long follow-up (mean, 59.7 months; SD, 19.6 months).
In addition to the primary subject groupings described above, we were interested in examining the possible influence of substantial differences in current age, age at onset of illness, duration of illness, and symptom changes on the stability of neuropsychological performance among the schizophrenic patients. Hence, we conducted a series of analyses in which we dichotomized the schizophrenic patients in terms of these characteristics. The definition of the symptom change groups and the resulting samples are described later. The other groupings included 22 elderly patients (age at study entry, Ն65 years; mean, 69.2 years; SD, 3.3 years) vs 120 younger patients (age at study entry, Ͻ65 years; mean, 43.7 years; SD, 13.7 years); 24 patients with late-onset schizophrenia (aged Ն45 years at onset of prodromal symptoms; mean, 55.0 years; SD, 5.6 years) vs 118 with earlier onset (onset at age Ͻ45 years; mean, 22.7 years; SD, 7.3 years); and 30 patients with a duration of illness less than 5 years (mean, 2.0 years; SD, 1.4 years) vs 105 subjects with a duration of illness of 5 years or more (mean, 23.6 years; SD, 12.5 years). We also dichotomized patients in terms of sex and initial level of neuropsychological functioning (low [global neuropsychological T-score, Յ39] vs high [global neuropsychological T-score, Ͼ45]) and anticholinergic use (receiving vs not receiving anticholinergic medication).
Repeated-measures analysis of variance (ANOVA) was used to examine effects of diagnosis (schizophrenic patients vs NCs) and length of follow-up (as noted above, short vs long) on changes in neuropsychological performance. These analyses were conducted on T-scores (to correct for changes attributable to the effects of normal aging during long-term follow-up) for the entire neuropsychological battery (global neuropsychological T-score) as well as for each of the specific neuropsychological ability areas. We also used repeated-measures ANOVA to examine the various pairs of schizophrenic subgroups on changes in global neuropsychological performance and the 7 ability domains.
To assess the relationship between clinical change and neuropsychological functioning, patients were categorized into 3 groups based on change in clinical symptom scores from baseline to follow-up. Patients whose clinical symptom score (either SAPS or SANS total score) fell in the lower 25% of the distribution were considered to have a "low" level of symptoms, those in the middle 50% were labeled "middle," and those in the upper 25% of the distribution were categorized as "high." To meet criteria for a clinically significant change in symptoms, a subject had to move at least 1 category from baseline to follow-up, and by at least 3 points. Separate analyses were conducted for the SAPS-and SANS-defined change groups.
We also examined significant decreases in global neuropsychological T-scores of individual subjects, by means of the reliable change index method with adjustments for practice effect. 59, 60 This approach involves constructing prediction intervals around each subject's expected follow-up score. The predicted follow-up score is the subject's baseline score, adjusted for practice effects among cognitively stable individuals (as determined from the mean change observed among the NCs). The boundary values of the prediction interval around the predicted follow-up score are determined by the normal variability of baseline to follow-up changes (SE of the difference) determined from the NC group. Specifically, 90% prediction intervals were built around these predicted follow-up scores by multiplying the SD of the difference among NCs by 1.64. Subjects whose observed follow-up scores were below the lower limits of the 90% prediction interval (ie, the bottom 5% of normal controls) were considered to have shown significant declines in neuropsychological functioning. These procedures were conducted twice: once to evaluate changes from baseline to first retest among all patients and NCs, and then again in terms of changes from the first to last neuropsychological assessment among subjects with long follow-ups.
Two-tailed tests were used for all analyses. To help avoid type I errors associated with multiple comparisons, significance was defined as PϽ.01.
(REPRINTED) ARCH GEN PSYCHIATRY/ VOL 58, JAN 2001 (76.7% vs 55.0%; 2 1,N = 206 = 10.29; P = .002) and white (94.2% vs 72.5%; 2 1,N = 206 = 15.66; PϽ.001). There were no significant differences between the 2 subgroups of NCs in the interval between the baseline to first-retest neuropsychological evaluation. More important, the same patterns of neuropsychological test-retest change were present for schizophrenic patients and NCs with vs without the Halstead-Reitan battery Average Impairment Rating score.
One concern about participant attrition in a longitudinal study is that nonrandom factors may influence who remains in the study, resulting in nonrepresentative (biased) samples. We used Mann-Whitney tests to compare the baseline characteristics of subjects who completed at least 1 follow-up evaluation with patients who dropped out after completing the baseline assessment. Demographic characteristics (except for age), baseline clinical symptoms and cognitive performance (including IQ), and global neuropsychological functioning did not differ between the groups. Patients who dropped out were, however, older than those with follow-up visits (mean ages, 57 and 48 years, respectively; Mann-Whitney PϽ.001).
TEST-RETEST RELIABILITY
The test-retest reliability coefficients (intraclass correlation coefficients) of neuropsychological and psychiatric rating scale scores for NCs and patients were highly significant within each group ( Table 2) . With the exception of Performance IQ (where the test-retest reliability was higher in the schizophrenic group), the magnitudes of the test-retest correlations for the patients were not significantly different from those observed among the NCs.
MAGNITUDE OF PRACTICE EFFECTS: BASELINE TO FIRST AND LAST REPEATED ASSESSMENT
There were no significant differences between schizophrenic patients and NCs with respect to practice effects (T-score at first follow-up visit minus T-score at baseline visit) for the WAIS-R IQs, neuropsychological summary scores, or neuropsychological ability area scores ( Table 3 ).
The Figure depicts the changes in global neuropsychological T-scores from baseline to last follow-up, for subgroups with short vs long follow-up periods. Regardless of length of follow-up, the test-retest changes for schizophrenic patients and NCs were essentially parallel lines. Repeated-measures ANOVAs confirmed this finding, not only for the global neuropsychological score but also for all neuropsychological ability areas. There were highly significant group effects (PϽ.001), and sometimes significant time effects (reflecting modest improvement because of practice), but no significant diagnostic group ϫ time interactions.
ADDITIONAL SCHIZOPHRENIC SUBGROUP COMPARISONS
To further examine the change in cognitive functioning over time, we compared longitudinal global neuropsychological performance changes in subgroups of schizophrenic subjects defined on the bases of demographic and clinical variables (as listed and defined above). These ANOVAs disclosed no significant group effects. As shown in Table 4 , with 1 exception there also were no significant groupϫ time interactions, indicating that the characteristics defining the various groups were not related *Values represent means (with SD) or proportions for all variables other than medication dosages; these are presented as medians for the subgroups taking the respective types of medication. Significance of differences was assessed with independent t tests for variables involving means and with Pearson 2 for those involving proportions. The mean daily dose of antipsychotic medication was 993.1 (SD, 1742.3; range, 29.0-12 250.0) mg CPZE. The mean daily anticholinergic dose was 9.4 (SD, 28.1; range, 0.5-200.0) mg BZE. Twenty-five patients were taking an atypical antipsychotic medication at some point in their participation in this longitudinal study (11 risperidone, 9 clozapine, 2 olanzapine, and 3 ramoxipride). Repeated-measures analysis of variance showed no significant differences in the stability of neuropsychological performance between these patients and the other patients. BPRS indicates Brief Psychiatric Rating Scale; SAPS and SANS, Scales for the Assessment of Positive and Negative Symptoms, respectively; CPZE, daily chlorpromazine equivalent 61 ; BZE, daily benztropine equivalent 62 ; and NA, not applicable.
(REPRINTED) ARCH GEN PSYCHIATRY/ VOL 58, JAN 2001 to changes in neuropsychological performance over time. The 1 significant interaction reflected the fact that the schizophrenic subgroup with short duration of illness (mean, 2 years at baseline) had a slightly larger neuropsychological improvement than the subgroup with long duration (mean, 24 years at baseline). The smaller "improvement" (practice effect) shown by the longduration group was the same as that of the NCs (both means, 1.3 T-score points).
Using the SAPS to categorize clinical change status resulted in 11 patients being classified as worse, 27 as better, and 78 as stable. With the use of repeated-measures ANOVAs, no significant groupϫtime interactions were found for the neuropsychological global score or for scores on any of the 7 ability areas ( Table 4 ). Categorization of schizophrenic patients on the basis of SANS scores yielded 19 subjects identified as significantly worse, 80 subjects as stable, and 17 subjects as better. The results of repeatedmeasures ANOVAs for the neuropsychological global score were similar to those with the SAPS change groups, ie, no significant groupϫtime interactions.
We also compared patients with initial high vs low global neuropsychological performance (global neuropsychological T-score Ն45 vs Յ39, respectively), and those with vs without tardive dyskinesia as defined by the Schooler and Kane criteria 63 and those used by Wad- *Values reflect the mean (and SD) of the difference scores between each subject's score at the first follow-up assessment, and that at baseline. Therefore, positive values reflect improved test performance. WAIS-R indicates Wechsler Adult Intelligence Scale−Revised.
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SUBJECTS WITH UNUSUAL DECREASES IN GLOBAL NEUROPSYCHOLOGICAL T-SCORES
The modified Reliable Change Index method, described above, was used to identify and compare the percentages of individual NCs and schizophrenic patients who evidenced unusual neuropsychological worsening from baseline to first retest. With the use of the 90% prediction interval, 10 NCs were so identified (about 5% of the total sample); the latter proportion did not differ significantly from the 5.6% of patients with schizophrenia who evidenced unusual worsening ( 2 1,N = 348 = 0.10; P=.75). The above procedures were also used to evaluate baseline to final follow-up scores of the 85 individual NCs and 67 patients with schizophrenia with follow-up intervals of 36 months or longer (mean, 59.7 months; SD, 68 months). Again, the proportion of patients below the 90% prediction interval was not significantly different from that of the NCs (7.5% vs 4.7%, respectively; 2 1,N=152 =0.51; P =.48).
COMMENT
To our knowledge, this is the first longitudinal study to compare comprehensive neuropsychological test results of large samples of NCs and patients with schizophrenia during a multiyear follow-up period. After comparing the two groups with respect to test-retest reliabilities, we attempted to determine whether the schizophrenic patients, or even a subset of that group, evidenced progressive neuropsychological decline.
Consistent with previous reports, 22, 65 presence of psychosis did not appear to affect the reliability of neuropsychological test performance. Across the entire neuropsychological battery, reliability estimates were quite high, and were at least as high for the schizophrenic group as for the NCs. This was true even though clinical symptoms were relatively variable over time (Table 2) , and even though the test-retest intervals were longer than those in most previous reliability studies with NCs. 50, 66 These stability results support the view that neuropsychological deficits in schizophrenia are stable traitlike dimensions of the disorder, rather than reflecting state-related features.
Acceptable test-retest reliability does not rule out the possibility that neuropsychological deficits may be progressive in at least some patients with schizophrenia. Our results, however, provided no evidence of a deteriorating neuropsychological course in the total schizophrenic group, or in subgroups defined on the basis of age, sex, early vs late or recent vs remote onset of illness, baseline level of neuropsychological impairment, or length of follow-up. In each analysis, the schizophrenic groups showed slight improvements that were comparable with those evidenced by the NCs, and these likely represented practice effects. Even rather extreme clinical changes did not appear to influence the subjects' neuropsychological performance.
Longitudinal research in institutional settings has shown evidence of neuropsychological decline in some low-functioning, chronically hospitalized patients with schizophrenia. [29] [30] [31] Even in those studies, however, such worsening was observed only in small subsets of the groups being followed up. In the absence of longitudinal data from a neurologically stable comparison group, it is unclear whether these observed neuropsychological changes represent true neuropsychological decline, as in a neurodegenerative disorder, or whether they represent the tail of the distribution of test-retest fluctuations in neurologically stable (albeit very low-functioning) persons. It might be argued that the types of change observed in these patients (eg, change in the rated level of dementia) are too gross to be considered "normal fluctuation" and are pathognomonic of a progressive disorder. During approximately a 4-year follow-up interval, however, Ivnik and colleagues 67 found remarkable test-retest differences in neuropsychological performances of some elderly subjects who did not have any neuromedical disorder likely to affect cognition, eg, on neuropsychological factor scores with IQ-type scaling, test-retest differences of 20 or more points were not unusual. Therefore, the outer range of possible fluctuation in performance of neurologically stable persons cannot be assumed and should be established by means of an appropriate comparison group.
The mean global neuropsychological score for our patient group was 1.62 SDs below that of NCs (Table 1) , consistent with the range of effect sizes in a recent metaanalytic review of studies comparing controls and schizophrenic patients. 5 Although severely demented patients were not represented in our sample, our "low-functioning" subgroup (n = 45; Table 4 ) was very significantly impaired (ie, more than 3 SDs below NCs on the global neuropsychological T-score).
Limitations of this study include absence of chronically institutionalized patients, and therefore its results may not be generalizable to that minority of patients (but most contemporary schizophrenic patients are not institutionalized). [68] [69] [70] Also, there was limited representation of elderly subjects, and subjects who evidenced substantial clinical change or incident tardive dyskinesias during follow-up (Table 4 ). Although relatively few of our patients were tested initially very early in the course of their illness, 2 recent studies of first-break schizophrenia showed no significant cognitive decline during the first several years of illness. 35, 36 Morover, despite the limited power associated with some of the subgroup analyses in the current study, the data summarized in Table 4 show that these various subject characteristics were associated with clinically trivial effect sizes for changes in cognitive performance. Considered together, the results of available longitudinal studies strongly suggest that the large majority of people with schizophrenia do not experience progressive neuropsychological decline after the initial onset of their illness. We found no evidence of such decline, even in our ambulatory patients with long follow-up, who were observed for an average of 5 years. It remains possible that a subset of patients with very poor outcome (not represented in our study) do experience progressive neuropsychological decline. Future research with this population should attempt to document such decline by ruling out nonsignificant fluctuations in performance as evidence of progressive impairment. This might be done by using neuropsychological norms for change developed with a similarly impaired but neurologically stable comparison group, and determining whether any unusual neuropsychological worsening in the schizophrenic patients remains stable or progresses further during a subsequent follow-up period. If future research should conclusively establish progressive neuropsychological decline in a subset of schizophrenic patients, questions arise as to why only a minority are so affected. Is this another example of the heterogeneous manifestations of a common disease, [71] [72] [73] [74] or are other factors involved, such as treatment history 75 or comorbid neuromedical conditions (eg, age-related neurodegenerative changes, possibly in combination with schizophrenia-related low "cognitive reserve")? 76 There is a need for larger, collaborative studies using the same methods with patients in different treatment settings.
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